C JUN, C FOS AND NEURONAL PROGRAMMED CELL DEATH
C JUN, C FOS AND NEURONAL PROGRAMMED CELL DEATH
批准号:
2431282
负责人:
Steven Estus
金额:
$10.17万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-08-01 至 2000-05-31
关键词:
antisense nucleic acid apoptosis binding proteins cAMP response element binding protein complementary DNA embryo /fetus tissue /cell culture gene induction /repression genetic promoter element immunofluorescence technique laboratory rat neurogenetics neuropharmacology neurotrophic factors oligonucleotides oncoproteins oxidative stress peptidylprolyl isomerase phosphoproteins polymerase chain reaction protooncogene sympathetic nervous system transfection /expression vector western blottings
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Programmed cell death (PCD) is a well-recognized developmental phenomenon
that occurs by a process of apoptosis. Recent evidence strongly suggests
that PCD also contributes to pathological conditions. Several lines of
evidence have indicated that PCD results from the expression of a specific
genetic program leading to proteins that kill the cell. We have identified
several genes whose expression in increased in sympathetic neurons
undergoing PCD in response to deprivation of the neurotrophic factor, NGF,
and many genes whose expression is decreased. We have presented evidence
that c-Jun, a transcription factor encoded by the one of the induced genes,
is required for neuronal PCD. We have also presented evidence that
implicate the Fos family as being necessary for apoptosis; in NGF-deprived
neurons, certain Fos family members, i.e., c-fos and fos B, are induced,
while other, potentially inhibitory family members, i.e., fra-1 and fra-2,
are repressed. These results led us to theorize that neuronal PCD depends
upon both the activation of certain genes, i.e., c-jun, and the repression
of other genes, i.e., fra-1 and fra-2. Since (i) the induction f c-jun is
the earliest detectable genetic event, (ii) c-Jun interacts with each Fos
family member, and (iii) c-Jun has been implicated specifically as
necessary for death, our current working hypothesis is that events that
induce c-jun, modulate the activity of c-Jun, and that emanate from the
actions of c-Jun, constitute critical portions of a biochemical and genetic
cascade that results in neuronal death. We propose a focused attack aimed
at evaluating this hypothesis.
We shall further define the roles of the jun and Fos family members in
neuronal death by using several molecular genetic approaches. We shall
analyze athe expression of these genes at athe protein level to investigate
possible post-transcriptional regulation. We shall examine the
protein:protein interactions among the Jun and Fos family members to
identify directly athe proteins that interact with c-Jun. We shall
evaluate whether agents that protect neurons from NGF deprivation, i.e.,
cAMP analogs and potassium depolarization, do so by activating CREB-2, a
transcription factor that these agents activate and that modulates c-Jun.
We shall determine the biochemical changes during apoptosis that depend on
c-Jun, to identify 'downstream" mechanisms of c-Jun action. We shall
identify the molecular and cellular mechanisms leading to the activation of
c-jun; this investigation will lead "upstream" in the temporal cascade of
events by evaluating the roles of oxidative stress and c-Jun
phosphorylation.
These studies will provide considerable insight into the role of the Jun
and Fos family members in neuronal PCD and athe overall mechanism of
neuronal PCD. Given the increasing evidence for a role of neuronal PCD in
pathological conditions of the nervous system, i.e., stroke, neurotoxicity,
and neurodegenerative disease, these insights may lead to strategies to
intervene pharmacologically to prevent or retard death in these conditions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
How does D2-CD33 reduce Alzheimer's disease risk?
-
批准号:10038417
-
项目类别:
-
资助金额:$42.08万
-
财政年份:2020
-
负责人:Steven Estus
-
依托单位:
The surprising impact of APOE alleles on gut microbiome: does altering the microbiome reduce AD risk?
-
批准号:9783096
-
项目类别:
-
资助金额:$61.02万
-
财政年份:2018
-
负责人:Steven Estus
-
依托单位:
Translating CD33 genetic mechanism into a novel Alzheimers therapeutic
-
批准号:8696452
-
项目类别:
-
资助金额:$30.65万
-
财政年份:2014
-
负责人:Steven Estus
-
依托单位:
Translating CD33 genetic mechanism into a novel Alzheimers therapeutic
-
批准号:9251728
-
项目类别:
-
资助金额:$30.75万
-
财政年份:2014
-
负责人:Steven Estus
-
依托单位:
Translating CD33 genetic mechanism into a novel Alzheimers therapeutic
-
批准号:9038210
-
项目类别:
-
资助金额:$30.75万
-
财政年份:2014
-
负责人:Steven Estus
-
依托单位:
APOE RECEPTOR SPLICING, GENETICS, AND AD
-
批准号:7580202
-
项目类别:
-
资助金额:$30.43万
-
财政年份:2009
-
负责人:Steven Estus
-
依托单位:
LDLR Genetics, Splicing and AD Risk
-
批准号:7272847
-
项目类别:
-
资助金额:$26.28万
-
财政年份:2006
-
负责人:Steven Estus
-
依托单位:
LDLR Genetics, Splicing and AD Risk
-
批准号:7626369
-
项目类别:
-
资助金额:$13.77万
-
财政年份:2006
-
负责人:Steven Estus
-
依托单位:
LDLR Genetics, Splicing and AD Risk
-
批准号:7150191
-
项目类别:
-
资助金额:$28.22万
-
财政年份:2006
-
负责人:Steven Estus
-
依托单位:
LDLR Genetics, Splicing and AD Risk
-
批准号:7440187
-
项目类别:
-
资助金额:$25.75万
-
财政年份:2006
-
负责人:Steven Estus
-
依托单位:
Urokinase-type plasminogen activator and Alzheimer's
-
批准号:6656286
-
项目类别:
-
资助金额:$10.07万
-
财政年份:2002
-
负责人:Steven Estus
-
依托单位:
UPA Polymorphisms as a Differential Risk Factor for AD
-
批准号:6624470
-
项目类别:
-
资助金额:$25.34万
-
财政年份:2002
-
负责人:Steven Estus
-
依托单位:
Urokinase-type plasminogen activator and Alzheimer's
-
批准号:6759994
-
项目类别:
-
资助金额:$10.4万
-
财政年份:2002
-
负责人:Steven Estus
-
依托单位:
UPA Polymorphisms as a Differential Risk Factor for AD
-
批准号:6475250
-
项目类别:
-
资助金额:$25.34万
-
财政年份:2002
-
负责人:Steven Estus
-
依托单位:
Urokinase-type plasminogen activator/Alzheimer's Disease
-
批准号:6550671
-
项目类别:
-
资助金额:$14.35万
-
财政年份:2002
-
负责人:Steven Estus
-
依托单位:
UPA Polymorphisms as a Differential Risk Factor for AD
-
批准号:6733569
-
项目类别:
-
资助金额:$25.34万
-
财政年份:2002
-
负责人:Steven Estus
-
依托单位:
C-JUN AND AMYLOID-INDUCED APOPTOSIS
-
批准号:2750954
-
项目类别:
-
资助金额:$17.01万
-
财政年份:1996
-
负责人:Steven Estus
-
依托单位:
C-JUN AND AMYLOID-INDUCED APOPTOSIS
-
批准号:2274856
-
项目类别:
-
资助金额:$16.26万
-
财政年份:1996
-
负责人:Steven Estus
-
依托单位:
C-JUN AND AMYLOID-INDUCED APOPTOSIS
-
批准号:2460666
-
项目类别:
-
资助金额:$16.35万
-
财政年份:1996
-
负责人:Steven Estus
-
依托单位:
C JUN, C FOS AND NEURONAL PROGRAMMED CELL DEATH
-
批准号:2273579
-
项目类别:
-
资助金额:$9.88万
-
财政年份:1995
-
负责人:Steven Estus
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: